Literature DB >> 20140891

Dendritic cells lentivirally engineered to overexpress interleukin-10 inhibit contact hypersensitivity responses, despite their partial activation induced by transduction-associated physical stress.

Verena Besche1, Nadine Wiechmann, Timo Castor, Stefanie Trojandt, Yvonne Höhn, Hanna Kunkel, Manuel Grez, Stephan Grabbe, Angelika B Reske-Kunz, Matthias Bros.   

Abstract

BACKGROUND: Dendritic cells (DCs) constitute an attractive target for immunotherapeutic approaches. Because DCs are largely refractory to transfection with plasmid DNA, several viral transduction protocols were established. The potential side-effects of lentiviral transduction on the phenotype and activation state of DCs left unstimulated after transduction have not been assessed. There is a need to analyse these parameters as a result of the requirement of using DCs with a low activation state for therapeutic strategies intended to induce tolerance.
METHODS: Lentivirally-transduced bone marrow (BM)-derived DCs (LV-DCs) in comparison with mock-transduced (Mock-DCs) and untreated DCs were analysed with regard to the induction of maturation processes on the RNA, protein and functional level. BM-DCs engineered to overexpress interleukin (IL)-10 were analysed for therapeutic potential in a mouse model of allergic contact dermatitis.
RESULTS: Compared with untreated DCs, Mock-DCs and LV-DCs displayed an altered gene expression signature. Mock-DCs induced a stronger T cell proliferative response than untreated DCs. LV-DCs did not further augment the T cell proliferative response, but induced a slightly different T cell cytokine pattern compared to Mock-DCs. Accordingly, the gene promoter of the DC maturation marker fascin mediated efficient expression of the model transgene IL-10 in unstimulated-transduced BM-DCs. Nevertheless, IL-10 overexpressing BM-DCs exerted tolerogenic activity and efficiently inhibited the contact hypersensitivity response in previously hapten-sensitized mice.
CONCLUSIONS: Lentiviral transduction of BM-DCs results in their partial activation. Nevertheless, the transduction of these DCs with a vector encoding the immunomodulatory cytokine IL-10 rendered them tolerogenic. Thus, lentivirally-transduced DCs expressing immunomodulatory molecules represent a promising tool for induction of tolerance.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20140891     DOI: 10.1002/jgm.1436

Source DB:  PubMed          Journal:  J Gene Med        ISSN: 1099-498X            Impact factor:   4.565


  5 in total

1.  Dual functions of prostaglandin D2 in murine contact hypersensitivity via DP and CRTH2.

Authors:  Yoshihiro Yamamoto; Shinobu Otani; Hiroyuki Hirai; Kinya Nagata; Kosuke Aritake; Yoshihiro Urade; Shuh Narumiya; Hiroo Yokozeki; Masataka Nakamura; Takahiro Satoh
Journal:  Am J Pathol       Date:  2011-05-10       Impact factor: 4.307

2.  Activation of T cell checkpoint pathways during β-cell antigen presentation by engineered dendritic cells promotes protection from type 1 diabetes.

Authors:  Radhika R Gudi; Nicolas Perez; Subha Karumuthil-Melethil; Gongbo Li; Chenthamarakshan Vasu
Journal:  Immunology       Date:  2022-04-22       Impact factor: 7.215

Review 3.  Induction of Interleukin-10 Producing Dendritic Cells As a Tool to Suppress Allergen-Specific T Helper 2 Responses.

Authors:  Stefan Schülke
Journal:  Front Immunol       Date:  2018-03-19       Impact factor: 7.561

4.  Generation of Powerful Human Tolerogenic Dendritic Cells by Lentiviral-Mediated IL-10 Gene Transfer.

Authors:  Michela Comi; Giada Amodio; Laura Passeri; Marta Fortunato; Francesca Romana Santoni de Sio; Grazia Andolfi; Anna Kajaste-Rudnitski; Fabio Russo; Luca Cesana; Silvia Gregori
Journal:  Front Immunol       Date:  2020-06-30       Impact factor: 7.561

5.  Cannabinoid Receptor 2 Modulates Maturation of Dendritic Cells and Their Capacity to Induce Hapten-Induced Contact Hypersensitivity.

Authors:  Evelyn Gaffal; Andrea M Kemter; Stefanie Scheu; Rafael Leite Dantas; Jens Vogt; Bernhard Baune; Thomas Tüting; Andreas Zimmer; Judith Alferink
Journal:  Int J Mol Sci       Date:  2020-01-11       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.